Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 30

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 30
---
in 18.2 protein, which is often expressed in gastric and pancreatic cancer cells. The U.S. FDA has granted Fast Track designation to IBI343 for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) that has relapsed and/or is refractory to one prior line of therapy. IBI3001 is a potential first-in-class bispecific ADC designed to target both EGFR and B7H3. The transaction, including any future exercise of the option, is subject to customary closing conditions, including regulatory approvals.

Update on Takeda’s Research Activities

– In October 2025, as part of a strategic portfolio prioritization process, Takeda announced the decision to discontinue its cell therapy efforts. Takeda will seek an external partner to leverage its cell therapy platform technologies and to further advance the company’s research and clinic-ready programs in this field. The company has no current active clinical trials utilizing cell therapy technology. Takeda will refocus near-term investments into programs that it believes can deliver transformative therapies to patients at increased speed and scale.

#### 3. Material Contracts
There were no decisions or agreements reached on important management matters, nor any material contracts executed, during the six-month period ended September 30, 2025.

<div align='center'>- 18 -</div>

Translation for reference purpose only

#### III. Information on the Company

#### 1. Information on the Company’s Shares
(1) Total number of shares and other related information

1) Total number of shares

| Class        |     | Total number of shares           
 authorized to be issued (Shares) |               |
| Common stock |     |                                  | 3,500,000,000 |
| Total        |     |                                  | 3,500,000,000 |

2) Number of shares issued

|              | Class |     | Number of shares outstanding 
   (As of September 30, 2025) |     |     | Number of shares outstanding as of the filling date 
                                  (October 30, 2025) |     |                                                                               | Stock exchange on which the Company is listed |                                                            |
|:-------------|:------|:----|-----------------------------:|:----|:----|----------------------------------------------------:|:----|:------------------------------------------------------------------------------|:----------------------------------------------|:-----------------------------------------------------------|
| Common stock |       |     |                1,590,985,809 |     |     |